Salivary gland cancers: current treatments, molecular characteristics and new therapies

References

• Davies L, Welch HG. Epidemiology of head and neck cancer in the United States. Otolaryngol. Head Neck Surg.135(3), 451–457 (2006).
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Riggs CE Jr, Cassisi NJ. Treatment of head and neck cancers. Cancer: Principles and Practice of Oncology (7th Edition). DeVita VT Jr, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 662–732 (2005).
   Google Scholar
• Licitra L, Grandi C, Prott FJ et al. Major and minor salivary glands tumours. Crit. Rev. Oncol. Hematol.45(2), 215–225 (2003).
   PubMed Web of Science ®Google Scholar
• Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Handbook (6th Edition). Springer, NY, USA 53–58 (2002).
   Google Scholar
• Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer103(12), 2544–2550 (2005).
   PubMed Web of Science ®Google Scholar
• Terhaard CH, Lubsen H, Van der Tweel I et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck26(8), 681–692; discussion 692–683 (2004).
   PubMed Web of Science ®Google Scholar
• Rizk S, Robert A, Vandenhooft A et al. Activity of chemotherapy in the palliative treatment of salivary gland tumors: review of the literature. Eur. Arch. Otorhinolaryngol.264(6), 587–594 (2007).
   PubMedGoogle Scholar
• Speight PM, Barrett AW. Salivary gland tumours. Oral Dis.8(5), 229–240 (2002).
   PubMed Web of Science ®Google Scholar
• Rapidis AD, Givalos N, Gakiopoulou H et al. Mucoepidermoid carcinoma of the salivary glands. Review of the literature and clinicopathological analysis of 18 patients. Oral Oncol.43(2), 130–136 (2007).
   PubMedGoogle Scholar
• Pires FR, de Almeida OP, de Araujo VC, Kowalski LP. Prognostic factors in head and neck mucoepidermoid carcinoma. Arch. Otolaryngol. Head Neck Surg.130(2), 174–180 (2004).
   PubMedGoogle Scholar
• Boahene DK, Olsen KD, Lewis JE et al. Mucoepidermoid carcinoma of the parotid gland: the Mayo clinic experience. Arch. Otolaryngol. Head Neck Surg.130(7), 849–856 (2004).
   PubMedGoogle Scholar
• Brandwein MS, Ivanov K, Wallace DI et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am. J. Surg. Pathol.25(7), 835–845 (2001).
   PubMed Web of Science ®Google Scholar
• Guzzo M, Andreola S, Sirizzotti G, Cantu G. Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann. Surg. Oncol.9(7), 688–695 (2002).
   PubMedGoogle Scholar
• Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer82(7), 1217–1224 (1998).
   PubMed Web of Science ®Google Scholar
• Press MF, Pike MC, Hung G et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res.54(21), 5675–5682 (1994).
   PubMed Web of Science ®Google Scholar
• Gibbons MD, Manne U, Carroll WR et al. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope111(8), 1373–1378 (2001).
   PubMedGoogle Scholar
• Handra-Luca A, Bilal H, Bertrand JC, Fouret P. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation. Am. J. Pathol.163(3), 957–967 (2003).
   PubMed Web of Science ®Google Scholar
• Tonon G, Modi S, Wu L et al. t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat. Genet.33(2), 208–213 (2003).
   PubMed Web of Science ®Google Scholar
• Komiya T, Park Y, Modi S et al. Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation. Oncogene25(45), 6128–6132 (2006).
   PubMedGoogle Scholar
• Okabe M, Miyabe S, Nagatsuka H et al. MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma. Clin. Cancer Res.12(13), 3902–3907 (2006).
   PubMedGoogle Scholar
• Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T. Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. Mod. Pathol.14, 1008–1014 (2001).
   PubMedGoogle Scholar
• Yin HF, Okada N, Takagi M. Apoptosis and apoptotic-related factors in mucoepidermoid carcinoma of the oral minor salivary glands. Pathol. Int.50(8), 603–609 (2000).
   PubMedGoogle Scholar
• Haddad R, Colevas AD, Krane JF et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A Phase II study. Oral Oncol.39(7), 724–727 (2003).
   PubMed Web of Science ®Google Scholar
• Glisson BS, Blumenschein G, Francisco M et al. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J. Clin. Oncol.23, S508 (2005).
   Google Scholar
• Gilbert J, Li Y, Pinto HA et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck28(3), 197–204 (2006).
   PubMed Web of Science ®Google Scholar
• Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol.24(17), 2673–2678 (2006).
   PubMed Web of Science ®Google Scholar
• da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, de Almeida OP, Kowalski LP. Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol.42(2), 139–146 (2006).
   PubMedGoogle Scholar
• Fordice J, Kershaw C, El-Naggar A, Goepfert H. Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch. Otolaryngol. Head Neck Surg.125(2), 149–152 (1999).
   PubMedGoogle Scholar
• Frierson HF Jr, El-Naggar AK, Welsh JB et al. Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma. Am. J. Pathol.161(4), 1315–1323 (2002).
   PubMedGoogle Scholar
• Nakashima D, Uzawa K, Kasamatsu A et al. Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands. Int. J. Cancer118(3), 704–713 (2006).
   PubMedGoogle Scholar
• Kasamatsu A, Endo Y, Uzawa K et al. Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses. Int. J. Biochem. Cell Biol.37(9), 1869–1880 (2005).
   PubMedGoogle Scholar
• Patel KJ, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM. Genes associated with early development, apoptosis and cell cycle regulation define a gene expression profile of adenoid cystic carcinoma. Oral Oncol.42(10), 994–1004 (2006).
   PubMedGoogle Scholar
• Lu YG, Zhou HY, Ding LC et al. [Analysis of differential expression genes related to different metastasis potential of adenoid cystic carcinoma using restriction fragments differential display PCR]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi23(5), 505–510 (2006).
   PubMedGoogle Scholar
• Chen W, Zhang HL, Shao XJ et al. Gene expression profile of salivary adenoid cystic carcinoma associated with perineural invasion. Tohoku J. Exp. Med.212(3), 319–334 (2007).
   PubMedGoogle Scholar
• Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett.154(1), 107–111 (2000).
   PubMed Web of Science ®Google Scholar
• Freier K, Flechtenmacher C, Walch A et al. Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol.41(9), 934–939 (2005).
   PubMedGoogle Scholar
• Hotte SJ, Winquist EW, Lamont E et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II consortium study. J. Clin. Oncol.23(3), 585–590 (2005).
   PubMed Web of Science ®Google Scholar
• Alcedo JC, Fabrega JM, Arosemena JR, Urrutia A. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck26(9), 829–831 (2004).
   PubMedGoogle Scholar
• Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J. Clin. Oncol.23(25), 6271–6273; author reply 6273–6274 (2005).
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther.82(23), 241–250 (1999).
   PubMed Web of Science ®Google Scholar
• Licitra LF, Locati LD, Potepan P et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): a monoinstitutional Phase II study. Proc. Am. Soc. Clin. Oncol.24, S291 (2005).
   Google Scholar
• Karja V, Syrjanen S, Kataja V, Syrjanen K. c-erbB-2 oncogene expression in salivary gland tumours. ORL J. Otorhinolaryngol. Relat. Spec.56(4), 206–212 (1994).
   PubMedGoogle Scholar
• Glisson B, Colevas AD, Haddad R et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin. Cancer Res.10(3), 944–946 (2004).
   PubMed Web of Science ®Google Scholar
• Shintani S, Funayama T, Yoshihama Y et al. Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res.15(6B), 2623–2626 (1995).
   PubMed Web of Science ®Google Scholar
• Agulnik M, Cohen EW, Cohen RB et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol.25(25), 3978–3984 (2007).
   PubMedGoogle Scholar
• Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol.42(8), 759–769 (2006).
   PubMedGoogle Scholar
• Shadaba A, Gaze MN, Grant HR. The response of adenoid cystic carcinoma to tamoxifen. J. Laryngol. Otol.111(12), 1186–1189 (1997).
   PubMed Web of Science ®Google Scholar
• Gallo O, Franchi A, Bianchi S et al. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer75(8), 2037–2044 (1995).
   PubMedGoogle Scholar
• Papadaki H, Finkelstein SD, Kounelis S et al. The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. Hum. Pathol.27(6), 567–572 (1996).
   PubMed Web of Science ®Google Scholar
• Zhu QR, White FH, Tipoe GL. p53 oncoprotein accumulation in adenoid cystic carcinoma of parotid and palatine salivary glands. Pathology29(2), 154–158 (1997).
   PubMed Web of Science ®Google Scholar
• Kiyoshima T, Shima K, Kobayashi I et al. Expression of p53 tumor suppressor gene in adenoid cystic and mucoepidermoid carcinomas of the salivary glands. Oral Oncol.37(3), 315–322 (2001).
   PubMedGoogle Scholar
• Alves FA, Pires FR, De Almeida OP, Lopes MA, Kowalski LP. PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours. Int. J. Oral Maxillofac. Surg.33(6), 593–597 (2004).
   PubMedGoogle Scholar
• Carlinfante G, Lazzaretti M, Ferrari S, Bianchi B, Crafa P. P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol. Res. Pract.200(11–12), 791–799 (2005).
   PubMedGoogle Scholar
• Karja VJ, Syrjanen KJ, Kurvinen AK, Syrjanen SM. Expression and mutations of p53 in salivary gland tumours. J. Oral. Pathol. Med.26(5), 217–223 (1997).
   PubMedGoogle Scholar
• Yamamoto Y, Wistuba II, Kishimoto Y, Virmani AK, Vuitch F. Loss of heterozygosity and microsatellite alterations in p53 and RB genes in adenoid cystic carcinoma of the salivary glands. Pathol. Int.48(4), 273–280 (1998).
   PubMedGoogle Scholar
• Uchida D, Begum NM, Almofti A et al. Frequent downregulation of 14-3-3σ protein and hypermethylation of 14-3-3σ gene in salivary gland adenoid cystic carcinoma. Br. J. Cancer91(6), 1131–1138 (2004).
   PubMedGoogle Scholar
• Jia L, Esguerra RL, Tang X et al. Prognostic value of apoptosis and apoptosis-associated proteins in salivary gland adenoid cystic carcinoma. Pathol. Int.54(4), 217–223 (2004).
   PubMedGoogle Scholar
• Norberg-Spaak L, Dardick I, Ledin T. Adenoid cystic carcinoma: use of cell proliferation, BCL-2 expression, histologic grade, and clinical stage as predictors of clinical outcome. Head Neck22(5), 489–497 (2000).
   PubMedGoogle Scholar
• Pramoonjago P, Baras AS, Moskaluk CA. Knockdown of Sox4 expression by RNAi induces apoptosis in ACC3 cells. Oncogene25(41), 5626–5639 (2006).
   PubMed Web of Science ®Google Scholar
• Kim KH, Chung PS, Rhee CS, Kim WH. The manifestation of proliferating cell nuclear antigen in adenoid cystic carcinoma. Arch. Otolaryngol. Head Neck Surg.120(11), 1221–1225 (1994).
   PubMedGoogle Scholar
• Lim JJ, Kang S, Lee MR et al. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J. Oral. Pathol. Med.32(9), 552–561 (2003).
   PubMedGoogle Scholar
• Zhang J, Peng B. In vitro angiogenesis and expression of nuclear factor κB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. BMC Cancer7, 95 (2007).
   PubMedGoogle Scholar
• Younes MN, Park YW, Yazici YD et al. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol. Cancer Ther.5(11), 2696–2705 (2006).
   PubMedGoogle Scholar
• Argiris A, Goldwasser MA, Burtness B et al. A Phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol.24(18S), 5573 (2006).
   Google Scholar
• Wahlberg P, Anderson H, Biorklund A, Moller T, Perfekt R. Carcinoma of the parotid and submandibular glands–a study of survival in 2465 patients. Oral Oncol.38(7), 706–713 (2002).
   PubMed Web of Science ®Google Scholar
• van Halteren HK, Top B, Mooi WJ, Balm AJ, Rodenhuis S. Association of H-ras mutations with adenocarcinomas of the parotid gland. Int. J. Cancer57(3), 362–364 (1994).
   PubMedGoogle Scholar
• Ohshiro K, Rayala SK, Williams MD, Kumar R, El-Naggar AK. Biological role of estrogen receptor beta in salivary gland adenocarcinoma cells. Clin. Cancer Res.12(20 Pt 1), 5994–5999 (2006).
   PubMedGoogle Scholar
• Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am. J. Clin. Pathol.119(6), 801–806 (2003).
   PubMed Web of Science ®Google Scholar
• Katopodi E, Patsouris E, Papanikolaou V et al. Immunohistochemical detection of epidermal growth factor and its receptor in salivary gland carcinomas. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.95(3), 266–268 (2003).
   PubMedGoogle Scholar
• van der Hulst RW, van Krieken JH, van der Kwast TH et al. Partial remission of parotid gland carcinoma after goserelin. Lancet344(8925), 817 (1994).
   PubMedGoogle Scholar
• Locati LD, Bossi P, Rinaldi GR et al. Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC). Ann. Oncol.38(Suppl. 3), 404 (2005).
   Google Scholar
• Jaehne M, Roeser K, Jaekel T et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer103(12), 2526–2533 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer77(2), 223–230 (1996).
   PubMed Web of Science ®Google Scholar
• Skalova A, Starek I, Vanecek T et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology42(4), 348–356 (2003).
   PubMedGoogle Scholar
• Locati LD, Rinaldi G, Bossi P et al. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol.41(1), 97–98 (2005).
   PubMedGoogle Scholar
• Vadlamudi RK, Balasenthil S, Sahin AA et al. Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum. Pathol.36(6), 670–675 (2005).
   PubMed Web of Science ®Google Scholar
• Hoang MP, Callender DL, Sola Gallego JJ et al. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Int. J. Oncol.19(4), 865–871 (2001).
   PubMedGoogle Scholar
• Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am. J. Surg. Pathol.24(4), 579–586 (2000).
   PubMedGoogle Scholar
• James GK, Pudek M, Berean KW, Diamandis EP, Archibald BL. Salivary duct carcinoma secreting prostate-specific antigen. Am. J. Clin. Pathol.106(2), 242–247 (1996).
   PubMed Web of Science ®Google Scholar
• Mukunyadzi P, Ai L, Portilla D, Barnes EL, Fan CY. Expression of peroxisome proliferator-activated receptor gamma in salivary duct carcinoma: immunohistochemical analysis of 15 cases. Mod. Pathol.16(12), 1218–1223 (2003).
   PubMedGoogle Scholar
• Sato K, Shimode Y, Itoi A, Ueda Y, Katsuda S. Salivary duct carcinoma of the parotid gland presenting KIT (CD117) overexpression. Histopathology51(1), 114–115 (2007).
   PubMedGoogle Scholar